Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Perfect

Showing results (101-110 of 160) with videos related to

Pageof 16
Sort By:
Antimicrobial Agents and Chemotherapy|February 19, 2000
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformansM Del Poeta, M C Cruz, M E Cardenas, et al.
Journal of Medical and Veterinary Mycology : Bi-Monthly Publication of the International Society for Human and Animal Mycology|January 1, 1992
A nationwide survey of clinical laboratory methodologies for fungal infectionsS D Goodwin, J Fiedler-Kelly, T H Grasela, et al.
Infection Control and Hospital Epidemiology|December 1, 1993
Cryptococcal ventricular-peritoneal shunt infection: clinical and epidemiological evaluation of two closely associated casesC W Ingram, H B Haywood, V M Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 1994
Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformansJ K Lodge, E Jackson-Machelski, D L Toffaletti, et al.
Medical Mycology|February 28, 2002
An auxotrophic pigmented Cryptococcus neoformans strain causing infection of the bone marrowD Schiappa, A Gueyikian, S Kakar, et al.
Antimicrobial Agents and Chemotherapy|December 6, 2006
Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tabletsE S Dodds Ashley, A K Zaas, A F Fang, et al.
The Journal of Infection|December 12, 2003
Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patientsW J Steinbach, W A Schell, J L Miller, et al.
AIDS (London, England)|March 1, 1996
Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapyA E Heald, G M Cox, W A Schell, et al.
Medical Mycology|February 13, 1999
Cryptococcus neoformans: virulence and host defencesJ R Perfect, B Wong, Y C Chang, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1998
In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformansW A Schell, G M De Almeida, R K Dodge, et al.
Pageof 16

Showing results (101-110 of 160) with videos related to

Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|February 19, 2000
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformansM Del Poeta, M C Cruz, M E Cardenas, et al.
Journal of Medical and Veterinary Mycology : Bi-Monthly Publication of the International Society for Human and Animal Mycology|January 1, 1992
A nationwide survey of clinical laboratory methodologies for fungal infectionsS D Goodwin, J Fiedler-Kelly, T H Grasela, et al.
Infection Control and Hospital Epidemiology|December 1, 1993
Cryptococcal ventricular-peritoneal shunt infection: clinical and epidemiological evaluation of two closely associated casesC W Ingram, H B Haywood, V M Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 1994
Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformansJ K Lodge, E Jackson-Machelski, D L Toffaletti, et al.
Medical Mycology|February 28, 2002
An auxotrophic pigmented Cryptococcus neoformans strain causing infection of the bone marrowD Schiappa, A Gueyikian, S Kakar, et al.
Antimicrobial Agents and Chemotherapy|December 6, 2006
Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tabletsE S Dodds Ashley, A K Zaas, A F Fang, et al.
The Journal of Infection|December 12, 2003
Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patientsW J Steinbach, W A Schell, J L Miller, et al.
AIDS (London, England)|March 1, 1996
Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapyA E Heald, G M Cox, W A Schell, et al.
Medical Mycology|February 13, 1999
Cryptococcus neoformans: virulence and host defencesJ R Perfect, B Wong, Y C Chang, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1998
In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformansW A Schell, G M De Almeida, R K Dodge, et al.
Pageof 16